4-Isopropyl-2-methyl-thiazolidine | 1314931-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-Isopropyl-2-methyl-thiazolidine
• 英文别名: 2-Methyl-4-isopropyl-thiazolidine；2-methyl-4-propan-2-yl-1,3-thiazolidine
• CAS: 1314931-36-6
• 化学式: C₇H₁₅NS
• mdl: MFCD19219836
• 分子量: 145.269
• InChiKey: ANWPSIBFGUQZEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-isopropyl-aziridine 、 乙醛 以25%的产率得到4-Isopropyl-2-methyl-thiazolidine
  参考文献：
  名称：

  Electron impact study of derivatives of thiazolidine

  摘要：

  DOI：

  10.1002/oms.1210230610

文献信息

• Small Molecule Drug Conjugates
  申请人：Philochem AG

  公开号：US20170035892A1

  公开（公告）日：2017-02-09

  A targeted therapeutic agent comprising a compound of formula I: B-L-D  (I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group.
• COMPOUNDS FOR TREATMENT OF CANCER
  申请人：LI WEI

  公开号：US20170226086A1

  公开（公告）日：2017-08-10

  The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
• COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Azura Ophthalmics Ltd.

  公开号：US20220332749A1

  公开（公告）日：2022-10-20

  Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
• US9884122B2
  申请人：——

  公开号：US9884122B2

  公开（公告）日：2018-02-06